Wisconsin Department of Safety and Professional Services
Division of Policy Development
4822 Madison Yards Way
PO Box 8366
Madison WI 53708-8366

Phone: 608-266-2112
Web: http://dsps.wi.gov
Email: dsps@wisconsin.gov

Tony Evers, Governor
Dan Hereth, Secretary

VIRTUAL/TELECONFERENCE
CONTROLLED SUBSTANCES BOARD
Virtual, 4822 Madison Yards Way, Madison
Contact: Tom Ryan (608) 266-2112
November 14, 2025

The following agenda describes the issues that the Board plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a description of the actions and deliberations of the Board.

AGENDA

10:00 A.M.

OPEN SESSION – CALL TO ORDER – ROLL CALL

A. Adoption of Agenda (1-3)

B. Approval of Minutes September 19, 2025 (4-5)

C. Reminders: Conflicts of Interests, Scheduling Concerns

D. Introductions, Announcements and Recognition

E. Administrative Matters – Discussion and Consideration
1) Department, Staff, and Board Updates
2) Board Members – Term Expiration Dates
   a. Barman, Subhadeep – 5/1/2019
   b. Bellay, Yvonne – DATCP Representative
   c. Bloom, Alan – 5/1/2020
   d. Eberhardy, Cullen – AG Representative
   e. Englebert, Doug – DHS Representative
   f. Gundersen, David – Dentistry Examining Board Representative
   g. Kane, Amanda – Board of Nursing Representative
   h. Majeed-Haqqi, Lubna – Medical Examining Board Representative
   i. Weitekamp, John – Pharmacy Examining Board Representative
3) Alternates
   a. Alton, Troy – Dentistry Examining Board Representative
   b. Leuthner, Steven – Medical Examining Board Representative
   c. Weinman, Robert – Board of Nursing Representative

F. Administrative Rule Matters – Discussion and Consideration (6-18)
1) Affirmative Action Order:
   a. CSB 2.015, Relating to Scheduling 7 Synthetic Benzimidazole-Opioids **(7-8)**
2) Scope Statement:
   a. CSB 2.014, Relating to scheduling 2 Synthetic Benzimidazole-Opioids **(9-10)**

b. CSB 2.013, Relating to Scheduling Dipentylone **(11-12)**

3) Preliminary Rule Draft:
   a. CSB 2.012, Scheduling 7 Fentanyl-Related Substances **(13-17)**
4) Pending or Possible Rulemaking Projects
   a. Rule Projects Chart **(18)**

G. Controlled Substance Scheduling Overview – Presentation (19-26)

H. Wisconsin Drug Trends Presentation – Cully Eberhardy, Technical Leader – Controlled Substances Unit, Wisconsin Department of Justice (27-39)

I. Prescription Drug Monitoring Program (PDMP) Updates – Discussion and Consideration (40-48)

1) WI ePDMP Operations
   a. Recent and Upcoming Releases
   b. EHR Integration Status
2) WI PDMP Outreach

J. DSPS Interdisciplinary Advisory Committee Liaison Report – Discussion and Consideration

1) Next Topic

K. Board Member Reports – Discussion and Consideration

1) Medical Examining Board
2) Dentistry Examining Board
3) Board of Nursing
4) Pharmacy Examining Board

L. Report from the Referral Criteria Work Group – Discussion and Consideration

M. Liaison Reports

N. Speaking Engagements, Travel, or Public Relations Requests, and Reports

O. Deliberation on Special Use Authorizations – Discussion and Consideration

P. Discussion and Consideration of Items Received After Preparation of the Agenda

1) Introductions, Announcements, and Recognition
2) Administrative Matters
3) Election of Officers
4) Appointment of Liaisons and Alternates
5) Delegation of Authorities
6) Informational Items
7) Division of Legal Services and Compliance (DLSC) Matters
8) Education and Examination Matters
9) Credentialing Matters
10) Practice Matters
11) Legislative and Administrative Rule Matters
12) Liaison Reports
13) Public Health Emergencies

14) Appearances from Requests Received or Renewed
15) Speaking Engagements, Travel, or Public Relations Requests, and Reports
16) Consulting with Legal Counsel

Q. Public Comments

CONVENE TO CLOSED SESSION to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider individual histories or disciplinary data (s. 19.85(1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.).

R. Deliberation on Special Use Authorizations – Discussion and Consideration

S. Consulting with Legal Counsel

RECONVENE TO OPEN SESSION IMMEDIATELY FOLLOWING CLOSED SESSION

T. Vote on Items Considered or Deliberated Upon in Closed Session if Voting is Appropriate

U. Open Session Items Noticed Above Not Completed in the Initial Open Session

ADJOURNMENT

NEXT MEETING: JANUARY 23, 2026

****

MEETINGS AND HEARINGS ARE OPEN TO THE PUBLIC, AND MAY BE CANCELLED WITHOUT NOTICE.

Times listed for meeting items are approximate and depend on the length of discussion and voting. All meetings are held virtually unless otherwise indicated. In-person meetings are typically conducted at 4822 Madison Yards Way, Madison, Wisconsin, unless an alternative location is listed on the meeting notice. In order to confirm a meeting or to request a complete copy of the board's agenda, please visit the Department website at https:\\dsps.wi.gov. The board may also consider materials or items filed after the transmission of this notice. Times listed for the commencement of any agenda item may be changed by the board for the convenience of the parties. The person credentialed by the board has the right to demand that the meeting at which final action may be taken against the credential be held in open session. Requests for interpreters for the hard of hearing, or other accommodations, are considered upon request by contacting the Affirmative Action Officer or reach the Meeting Staff by calling 608-267-7213.

VIRTUAL/TELECONFERENCE
CONTROLLED SUBSTANCES BOARD
MEETING MINUTES
SEPTEMBER 19, 2025

PRESENT: Subhadeep Barman, Yvonne Bellay, Alan Bloom, Cullen Eberhardy, Amanda Kane, Lubna Majeed-Haqqi, John Weitekamp

ABSENT: Doug Englebert, David Gundersen

STAFF: Tom Ryan, Executive Director; Jameson Whitney, Legal Counsel; Nilajah Hardin, Administrative Rules Coordinator; Brenda Taylor, Board Services Supervisor; and other DSPS Staff

CALL TO ORDER

Alan Bloom, Vice Chairperson, called the meeting to order at 10:00 a.m. A quorum was confirmed with seven (7) members present.

ADOPTION OF AGENDA

MOTION: John Weitekamp moved, seconded by Yvonne Bellay, to adopt the Agenda as amended. Motion carried unanimously.

APPROVAL OF MINUTES OF JULY 11, 2025

MOTION: Subhadeep Barman moved, seconded by John Weitekamp, to adopt the Minutes of July 11, 2025, as published. Motion carried unanimously.

PRELIMINARY PUBLIC HEARING ON STATEMENT OF SCOPE: SS 055-25 ON CSB 2.012, RELATING TO SCHEDULING 7 FENTANYL-RELATED SUBSTANCES

MOTION: Yvonne Bellay moved, seconded by Cullen Eberhardy, to affirm the Board has provided an opportunity to receive public comments concerning Scope Statement (SS) 055-25 on CSB 2.012, Relating to Scheduling 7 Fentanyl-Related Substances. Additionally, after consideration of all public comments and feedback the Board approves SS 055-25 for implementation. Motion carried unanimously.

ADMINISTRATIVE RULE MATTERS

Affirmative Action Order

CSB 2.013, Relating to Scheduling Dipentylone

MOTION: Subhadeep Barman moved, seconded by Yvonne Bellay, to approve the affirmative action order adding Dipentylone as a schedule I controlled substance. The order shall take effect upon publication in the Administrative Register. Motion carried unanimously.

CSB 2.014, Relating to Scheduling 2 Synthetic Benzimidazole-Opioids

MOTION: Subhadeep Barman moved, seconded by Cullen Eberhardy, to approve the affirmative action order adding N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances. The order shall take effect upon publication in the Administrative Register. Motion carried unanimously.

Final Rule Draft and Legislative Report

CSB 2.011, Scheduling Ethylphenidate

MOTION: Subhadeep Barman moved, seconded by Yvonne Bellay, to approve the Legislative Report and Draft for Clearinghouse Rule Clearinghouse Rule 25-060 (CSB 2.011), Relating to Scheduling Ethylphenidate for submission to the Governor's Office for approval, notification to the Legislature, and approval of the Adoption Order to the Legislative Reference Bureau for publication. Motion carried unanimously.

ADJOURNMENT

MOTION: Yvonne Bellay moved, seconded by Subhadeep Barman, to adjourn the meeting. Motion carried unanimously.

The meeting adjourned at 10:31 a.m.

State of Wisconsin
Department of Safety & Professional Services
AGENDA REQUEST FORM

1) Name and title of person submitting the request:	2) Date when request submitted:
Nilajah Hardin **Administrative Rules Coordinator**	**11/4/25** **Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting**

3) Name of Board, Committee, Council, Sections:

Controlled Substances Board

4) Meeting Date:	5) Attachments:	6) How should the item be titled on the agenda page?
11/14/25	☒ Yes ☐ No	**Administrative Rule Matters – Discussion and Consideration** 1. **Affirmative Action Order:** a. **CSB 2.015, Relating to Scheduling 7 Synthetic Benzimidazole-Opioids** 2. **Scope Statement:** a. **CSB 2.014, Relating to scheduling 2 Synthetic Benzimidazole-Opioids** b. **CSB 2.013, Relating to Scheduling Dipentylone** 3. **Preliminary Rule Draft:** a. **CSB 2.012, Scheduling 7 Fentanyl-Related Substances** 4. **Pending or Possible Rulemaking Projects** a. **Rule Projects Chart**

7) Place Item in:	8) Is an appearance before the Board being scheduled? *(If yes, please complete **Appearance Request** for Non-DSPS Staff)*	9) Name of Case Advisor(s), if required:
☒ Open Session ☐ Closed Session	☐ Yes ☒ No	**N/A**

10) Describe the issue and action that should be addressed:

Review and take action on Scope Statement, Preliminary Rules Drafts, and Final Rule Drafts.

Attachments:

- Affirmative Action Order – CSB 2.015
- Scope Statement – CSB 2.013 and 2.014
- Preliminary Rule Draft – CSB 2.012
- Rule Projects Chart

(All Board Rule Projects can be Viewed Here if Needed: https://dsps.wi.gov/Pages/RulesStatutes/PendingRules.aspx)

11) Authorization

Nilajah D. Hardin — 11/4/25

Signature of person making this request **Date**

Supervisor (if required) **Date**

Executive Director signature (indicates approval to add post agenda deadline item to agenda) **Date**

Directions for including supporting documents:

1. **This form should be attached to any documents submitted to the agenda.**
2. **Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.**
3. **If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.**

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING	:	AFFIRMATIVE ACTION
PROCEEDINGS BEFORE THE	:	ORDER OF THE
CONTROLLED SUBSTANCES BOARD	:	CONTROLLED SUBSTANCES BOARD

FINDINGS

1. On October 15, 2025, the Department of Justice, Drug Enforcement Administration published its temporary scheduling order in the Federal Register to scheduling the following 7 Synthetic-Benzimidazole-Opioids in schedule I of the federal Controlled Substances Act:

- Ethyleneoxynitazene
- Methylenedioxynitazene
- 5-methyl Etodesnitazene
- N-desethyl Etonitazene
- N-desethyl Protonitazene
- N,N-dimethylamino Etonitazene
- N-pyrrolidino Isotonitazene

The scheduling action is effective October 15, 2025.

2. The Controlled Substances Board did not receive an objection to similarly listing the above 7 Synthetic-Benzimidazole-Opioids as schedule I controlled substances under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing the above 7 Synthetic-Benzimidazole-Opioids as schedule I controlled substances.

3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rulemaking, listing the above 7 Synthetic-Benzimidazole-Opioids as schedule I controlled substances.

ORDER

Pursuant to s. 961.11 (4), Stats., the Controlled Substances Board by affirmative action similarly treats the above 7 Synthetic-Benzimidazole-Opioids under chapter 961, Stats. by creating the following:

CSB 2.015 Addition of 7 Synthetic Benzimidazole-Opioids to Schedule I. **(1)** Section 961.14 (2) (xm) 1m., 5m., 5p., 7b., 7h., 7k., and 8b. are created to read:

961.14 (2) (xm) 1m. Ethyleneoxynitazene (2-(2-((2,3-dihydrobenzofuran-5-yl)methyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine).

5m. Methylenedioxynitazene or 3',4'-methylenedioxynitazene (2-(2-(benzodioxol-5-ylmethyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine).

5p. 5-methyl etodesnitazene (2-(2-(4-ethoxybenzyl)-5-methyl-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine).

7b. N-desethyl etonitazene (2-(2-(4-ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N-ethyethan-1-amine).

7h. N-desethyl protonitazene (N-ethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine).

7k. N,N-dimethylamino etonitazene (2-(2-(4-ethoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-dimethylethan-1-amine).

8b. N-pyrrolidino isotonitazene (2-(4-isopropoxybenzyl)-5-nitro-1-(2-(pyrrolindin-1-yl)ethyl)-1H-benzimidazole).

This order shall become effective upon publication in the Administrative Register. The order expires upon promulgation of a final rule.

Dated _____

_____
Doug Englebert, Chair
Controlled Substances Board

STATEMENT OF SCOPE

CONTROLLED SUBSTANCES BOARD

Rule No.: CSB 2.014

Relating to: Scheduling 2 Synthetic Benzimidazole-Opioids

Rule Type: Permanent

1. Finding/nature of emergency: N/A

2. Detailed description of the objective of the proposed rule:
The objective of the proposed rule is to add N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances under s. 961.11 (4), Stats.

3. Description of the existing policies relevant to the rule, new policies proposed to be included in the rule, and an analysis of policy alternatives:
On August 15, 2025, the Department of Justice, Drug Enforcement Administration published its temporary scheduling order in the Federal Register adding N-pyrrolidino metonitazene and N-pyrrolidino protonitazene to schedule I of the federal Controlled Substances Act. The scheduling action was effective August 15, 2025. The Controlled Substances Board did not receive an objection to similarly N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.13 and omitting the notice of proposed rulemaking, listing N-pyrrolidino metonitazene and N-pyrrolidino protonitazene as schedule I controlled substances.

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats N-pyrrolidino metonitazene and N-pyrrolidino protonitazene under chapter 961, Stats. by creating the following:

CSB 2.014 Addition of 2 Synthetic Benzimidazole-Opioids to Schedule I. Section 961.14 (2) (xm) 8e. and 8m., Stats., are created to read:

> **961.14 (2) (xm) 8e.** N-pyrrolidino metonitazene also known as metonitazepyne (2-(4-methyoxbenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).
>
> **961.14 (2) (xm) 8m.** and N-pyrrolidino protonitazene also known as protonitazepyne (5-nitro-2-(4-propoxybenzyl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole).

The Affirmative Action order, dated September 29, 2025, took effect on October 6, 2025, upon publication in the Administrative Register and expires upon promulgation of a final rule.

4. Detailed explanation of statutory authority for the rule:
Section 961.11 (1), Stats. provides that "[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227."

Section 961.11(4), Stats. provides that "[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of

temporary scheduling under 21 USC 811 (h), unless within that 30−day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2)."

5. Estimate of amount of time that state employees will spend developing the rule and of other resources necessary to develop the rule:
Approximately 80 hours.

6. List with description of all entities that may be affected by the proposed rule:
Law enforcement, district attorney offices, Dept of Justice, state courts and the Controlled Substances Board.

7. Summary and preliminary comparison with any existing or proposed federal regulation that is intended to address the activities to be regulated by the proposed rule:
On August 15, 2025, the Department of Justice, Drug Enforcement Administration published its temporary scheduling order in the Federal Register adding N-pyrrolidino metonitazene and N-pyrrolidino protonitazene to schedule I of the federal Controlled Substances Act. The scheduling action was effective August 15, 2025.

8. Anticipated economic impact of implementing the rule: None to minimal.

Contact Person: Nilajah Hardin, Administrative Rules Coordinator, DSPSAdminRules@wisconsin.gov

Approved for publication:	Approved for implementation:
_____	_____
Authorized Signature	Authorized Signature
_____	_____
Date Submitted	Date Submitted

STATEMENT OF SCOPE

CONTROLLED SUBSTANCES BOARD

Rule No.: CSB 2.013

Relating to: Scheduling Dipentylone

Rule Type: Permanent

1. Finding/nature of emergency: N/A

2. Detailed description of the objective of the proposed rule:
The objective of the proposed rule is to add Dipentylone to schedule I under ch. 961, Stats.

3. Description of the existing policies relevant to the rule, new policies proposed to be included in the rule, and an analysis of policy alternatives:
On August 8, 2025, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register adding Dipentylone to schedule I of the federal Controlled Substances Act. The scheduling action was effective August 8, 2025. The Controlled Substances Board did not receive an objection to similarly listing Ethylphenidate in schedule I under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing Dipentylone as a schedule I controlled substance. Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Dipentylone under chapter 961, Stats. by creating the following:

CSB 2.013 Addition of Dipentylone to Schedule I. Section 961.14 (7) (L) 41., Stats., is created to read:

> **961.14 (7) (L) 41.** 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one, commonly known as Dipentylone or N,N-dimethylpentylone.

The Affirmative Action order, dated September 29, 2025, took effect on October 6, 2025, upon publication in the Administrative Register and expires upon promulgation of a final rule.

4. Detailed explanation of statutory authority for the rule:
Section 961.11 (1), Stats. provides that "[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227."

Section 961.11(4), Stats. provides that "[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30−day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2)."

5. Estimate of amount of time that state employees will spend developing the rule and of other resources necessary to develop the rule:
Approximately 80 hours.

6. List with description of all entities that may be affected by the proposed rule:
Law enforcement, district attorney offices, Dept of Justice, state courts and the Controlled Substances Board.

7. Summary and preliminary comparison with any existing or proposed federal regulation that is intended to address the activities to be regulated by the proposed rule:
On August 8, 2025, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register adding Dipentylone to schedule I of the federal Controlled Substances Act. The scheduling action was effective August 8, 2025.

8. Anticipated economic impact of implementing the rule: None to minimal.

Contact Person: Nilajah Hardin, Administrative Rules Coordinator, DSPSAdminRules@wisconsin.gov

Approved for publication:	Approved for implementation:
_____	_____
Authorized Signature	Authorized Signature
_____	_____
Date Submitted	Date Submitted

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING PROCEEDINGS BEFORE THE CONTROLLED SUBSTANCES BOARD	:	PROPOSED ORDER OF THE CONTROLLED SUBSTANCES BOARD ADOPTING RULES (CLEARINGHOUSE RULE)

PROPOSED ORDER

An order of the Controlled Substances Board to create CSB 2.012, relating to scheduling seven fentanyl-related substances.

Analysis prepared by the Department of Safety and Professional Services.

ANALYSIS

Statutes interpreted: s. 961.14, Stats.

Statutory authority: s. 961.11 (1) and (4), Stats.

Explanation of agency authority:
Section 961.11 (1), Stats. provides that "[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227."

Section 961.11(4), Stats. provides that "[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30−day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2)."

Related statute or rule: s. 961.14, Stats.

Summary of, and comparison with, existing or proposed federal regulation:
On December 30, 2024, the Department of Justice, Drug Enforcement Administration published its temporary scheduling order in the Federal Register adding the seven fentanyl-related substances listed above to schedule I of the federal Controlled Substances Act. The scheduling action was effective December 30, 2024.

Plain language analysis:
The objective of the proposed rule is to schedule the following seven fentanyl-related substances as schedule I controlled substances under s. 961.11 (4), Stats:

- Para-chlorofentanyl
- Ortho-chlorofentanyl
- Meta-fluorofuranyl fentanyl
- Ortho-methylcyclopropyl fentanyl
- Beta-methylacetyl fentanyl
- Tetrahydrothiofuranyl fentanyl
- Para-fluoro valeryl fentanyl

The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.13 and omitting the notice of proposed rulemaking, listing the above seven fentanyl-related substances as schedule I controlled substances. Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats the above seven fentanyl-related substances under chapter 961, Stats. by creating the following:

> **CSB 2.012 Addition of 7 Fentanyl Related Substances to Schedule I**. **(1)** Section 961.14 (2) (nd) 8m, 12p, 16h, 16q, 16r, 17d, and 18m are created to read:
>
> 961.14 (2) (nd) 8m. Beta-methylacetyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)acetamide);
>
> 12p. Meta-fluorofuranyl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
>
> 16h. Ortho-chlorofentanyl (N-(2-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
>
> 16q. Ortho-methylcyclopropyl fentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
>
> 16r. Para-chlorofentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide;
>
> 17d. Para-fluoro valeryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentanamide);

18m. Tetrahydrothiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrothiophen-2-carboxamide);

The Affirmative Action order, dated March 18, 2025, took effect on March 31, 2025, upon publication in the Administrative Register and expires upon promulgation of a final rule.

Summary of public comments received on statement of scope and a description of how and to what extent those comments and feedback were taken into account in drafting the proposed rule: N/A

Comparison with rules in adjacent states:
Illinois: Illinois has not listed the seven fentanyl-related substances included in this rule as schedule I controlled substances [720 Illinois Compiled Statutes 570/204].

Iowa: Iowa has not listed the seven fentanyl-related substances included in this rule as schedule I controlled substances [Iowa Code s. 124.204].

Michigan: Michigan has not listed the seven fentanyl-related substances included in this rule as schedule I controlled substances [Michigan Compiled Laws s. 333.7212].

Minnesota: Minnesota has not listed the seven fentanyl-related substances included in this rule as schedule I controlled substances [Minnesota Statutes s. 152.02 (2)].

Summary of factual data and analytical methodologies:
The methodology was to schedule the following seven fentanyl-related substances to conform with the federal Controlled Substances Act:

- Para-chlorofentanyl
- Ortho-chlorofentanyl
- Meta-fluorofuranyl fentanyl
- Ortho-methylcyclopropyl fentanyl
- Beta-methylacetyl fentanyl
- Tetrahydrothiofuranyl fentanyl
- Para-fluoro valeryl fentanyl

Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:
The proposed rule will be posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals.

Fiscal Estimate and Economic Impact Analysis:
The fiscal estimate and economic impact analysis will be attached upon completion.

Effect on small business:

These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department's Regulatory Review Coordinator may be contacted by email at Jennifer.Garrett@wisconsin.gov, or by calling (608) 266-2112.

Agency contact person:
Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, Wisconsin 53708; email at DSPSAdminRules@wisconsin.gov.

Place where comments are to be submitted and deadline for submission:
Comments may be submitted to Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, Madison, WI 53708-8366, or by email to DSPSAdminRules@wisconsin.gov. Comments must be received by (date) to be included in the record of rulemaking proceedings.

TEXT OF RULE

SECTION 1. CSB 2.012 is created to read:

CSB 2.012 Addition of 7 Fentanyl Related Substances to Schedule I. **(1)** Section 961.14 (2) (nd) 8m, 12p, 16h, 16q, 16r, 17d, and 18m are created to read:

> **961.14 (2) (nd)** 8m. Beta-methylacetyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)acetamide);
>
> 12p. Meta-fluorofuranyl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
>
> 16h. Ortho-chlorofentanyl (N-(2-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
>
> 16q. Ortho-methylcyclopropyl fentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
>
> 16r. Para-chlorofentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide;
>
> 17d. Para-fluoro valeryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentanamide);
>
> 18m. Tetrahydrothiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrothiophen-2-carboxamide);

SECTION 2. EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

(END OF TEXT OF RULE)

Controlled Substances Board
Rule Projects (updated 11/4/25)

CH Rule Number	Scope Number	Scope Expiration Date	Code Chapter Affected	Relating Clause	Stage of Rule Process	Next Step
25-021	113-24	06/02/2027	CSB 2.009	Scheduling 2 Synthetic Benzimidazole-Opioids	Effective 10/01/25	N/A
25-060	016-25	09/10/2027	CSB 2.010 (Renumbered to 2.011)	Scheduling Ethylphenidate	Adoption Order Submitted for Publication on 10/16/25	Rule Effective Date TBD
Not Assigned Yet	055-25	02/25/2028	CSB 2.011 (Renumbered to 2.012)	Scheduling 7 Fentanyl-related Substances	Preliminary Rule Draft Reviewed at 11/14/25 Meeting	Submission for EIA Comment Period and Clearinghouse Review
Not Assigned Yet	Not Assigned Yet	TBD	CSB 2.013	Scheduling Dipentylone	Scope Statement Reviewed at 11/14/25 Meeting	Submission for Governor's Office Approval and Publication (Preliminary Public Hearing likely to be Ordered by JCRAR)
Not Assigned Yet	Not Assigned Yet	TBD	CSB 2.014	Scheduling 2 Synthetic Benzimidazole-Opioids	Scope Statement Reviewed at 11/14/25 Meeting	Submission for Governor's Office Approval and Publication (Preliminary Public Hearing likely to be Ordered by JCRAR)
Not Assigned Yet	Not Assigned Yet	TBD	CSB 2.015	Scheduling 7 Synthetic Benzimidazole-Opioids	Affirmative Action Order reviewed at 11/14/25 Meeting	Affirmative Action Order Submission for Publication and Drafting of Scope Statement

State of Wisconsin
Department of Safety & Professional Services
AGENDA REQUEST FORM

1) Name and title of person submitting the request:	2) Date when request submitted:
Nilajah Hardin **Administrative Rules Coordinator**	**11/4/25** **Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting**

3) Name of Board, Committee, Council, Sections:

Controlled Substances Board

4) Meeting Date:	5) Attachments:	6) How should the item be titled on the agenda page?
11/14/25	☒ Yes ☐ No	**Controlled Substance Scheduling Overview**

7) Place Item in:	8) Is an appearance before the Board being scheduled? *(If yes, please complete Appearance Request for Non-DSPS Staff)*	9) Name of Case Advisor(s), if required:
☒ Open Session ☐ Closed Session	☐ Yes ☒ No	**N/A**

10) Describe the issue and action that should be addressed:

Attachments: 2025 CSB Rules – Presentation (PowerPoint File)

11) Authorization

Nilajah D. Hardin 11/4/25

Signature of person making this request **Date**

Supervisor (if required) **Date**

Executive Director signature (indicates approval to add post agenda deadline item to agenda) **Date**

Directions for including supporting documents:
1. **This form should be attached to any documents submitted to the agenda.**
2. **Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.**
3. **If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.**

CONTROLLED SUBSTANCE SCHEDULING OVERVIEW

Nilajah Hardin

Administrative Rules Coordinator, DSPS

WHAT IS SCHEDULING?

- Process Completed by the Controlled Substances Board
- Drug with the potential for abuse designated as a controlled substance in WI
- Analogs of a substance can also be scheduled

Schedule I	Heroin, PCP, LSD
Schedule II	Methamphetamine, Cocaine, Opiates
Schedule III	Barbiturates, Anabolic Steroids
Schedule IV	Benzodiazepines, Ephedrine, Tramadol
Schedule V	Pseudoephedrine

SCHEDULING IN WI

SCHEDULING DRUGS AS CONTROLLED SUBSTANCES

1. Standard Scheduling
2. Emergency Scheduling
3. Scheduling Based on Federal Action

STANDARD SCHEDULING

- "The 8 Questions"
  - Potential for abuse
  - Scientific evidence of pharmacological effect
  - Current scientific knowledge on the substance
  - History and current pattern of abuse
  - Scope, duration and significance of abuse
  - Risk to public health
  - Potential to produce psychological or physical dependence
  - Whether the substance is an immediate precursor of an already scheduled substance

EMERGENCY SCHEDULING

- 3 Factors
  - History and current pattern of abuse for the drug
  - Scope, duration, and significance of abuse
  - Risk to public health
- Requested by a district attorney prosecuting a case
- Emergency Rules Process – drug scheduled for 1 year
- Permanent Rules Process - must be in place before emergency rule expires

SCHEDULING BASED ON FEDERAL ACTION

- Affirmative Action Process
  - DEA schedules a drug and it's published in the Federal Register
  - Board must wait 30 days from DEA publication before scheduling
  - Board approves and publishes an Affirmative Action Order
  - Affirmative Action Order schedules drug into the same schedule under WI
  - Affirmative Action Order is effective upon publication until permanent rule goes into effect
  - Board then follows Permanent Rules Process

State of Wisconsin
Department of Safety & Professional Services

AGENDA REQUEST FORM

1) Name and title of person submitting the request: DSPS		**2) Date when request submitted:** 8/28/2024 **Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting**
3) Name of Board, Committee, Council, Sections: Controlled Substances Board		
4) Meeting Date: 11/14/2024	**5) Attachments:** ☒ Yes ☐ No	**6) How should the item be titled on the agenda page?** Drug Trends Presentation • Cullen Eberhardy, CSB Member, Wisconsin Department of Justice
7) Place Item in: ☒ Open Session ☐ Closed Session	**8) Is an appearance before the Board being scheduled?** *(If yes, please complete Appearance Request for Non-DSPS Staff)* ☒ Yes, Board Member Cullen Eberhardy ☐ No	**9) Name of Case Advisor(s), if applicable:** N/A
10) Describe the issue and action that should be addressed: Cullen Eberhardy, Board Member Wisconsin Department of Justice State Crime Technical Leader, – Controlled Substances Unit, will deliver a presentation on drug trends.		
11) Authorization		
Signature of person making this request		**Date**
Supervisor (Only required for post agenda deadline items)		**Date**
Executive Director signature (Indicates approval for post agenda deadline items)		**Date**

Directions for including supporting documents:
1. **This form should be saved with any other documents submitted to the Agenda Items folders.**
2. **Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.**
3. **If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.**

Department of Justice

Wisconsin State Crime Laboratories

Drug Trends in Wisconsin

Cully Eberhardy
Technical Leader – Controlled Substances Unit

Controlled Substance Techniques

Screening Tests (Category C)

Color tests, Microscopic exam, and Pharmaceutical Identifiers

Indicative Tests (Category B)

GC and Thin Layer Chromatography

Confirmatory Tests (Category A)

FTIR, GC/IR, and GC/MS

Conclusions

Identification

Substance of interest is identical to a standard substance

- Positive A + B test

Indication

Did not meet requirements for identification

- No standard available
- Weak sample
- Difficult matrix

Not typically included in stat tracking

Methamphetamine



Delta-9-Tetrahydrocannabinol



Cocaine


Drug Types Identified by Year
Drug Type Count
1000
500
324
757
801
799
954
1178
932
578
859
1306
2012
2014
2016
2018
2020
2022
2024
Year

Heroin


Drug Types Identified by Year
Drug Type Count
1000
500
349
1005
1141
1127
1209
1325
764
472
314
259
2012
2014
2016
2018
2020
2022
2024
Year

Fentanyl


Drug Types Identified by Year
Drug Type Count
1000
500
0
2012
2014
2016
2018
2020
2022
2024
Year
2
29
50
237
401
515
694
681
760
1034

Nitazenes



N-desethyl Etonitazene
Added to federal CSA 10/15/25



N-Pyrrolidino Metonitazene
961.14(2)(xm)8e



N-Pyrrolidino Protonitazene
961.14(2)(xm)8m

Other Compounds



BTMPS

Bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate

Not a controlled substance



Medetomidine

Not a controlled substance

Questions

Cully Eberhardy
1578 S. 11th St.
Milwaukee, WI 53204
(414)382-7500
Cullen.Eberhardy@wisdoj.gov


WISCONSIN STATE CRIME LABORATORIES
MADISON
WAUSAU
MILWAUKEE

Thank You!

State of Wisconsin
Department of Safety & Professional Services

AGENDA REQUEST FORM

1) Name and title of person submitting the request:	2) Date when request submitted:
Marjorie Liu Program Lead, PDMP	11/04/2025 Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting

3) Name of Board, Committee, Council, Sections:

Controlled Substances Board

4) Meeting Date:	5) Attachments:	6) How should the item be titled on the agenda page?
11/14/2025	☒ Yes ☐ No	Prescription Drug Monitoring Program (PDMP) Updates – Discussion and Consideration

7) Place Item in:	8) Is an appearance before the Board being scheduled? *(If yes, please complete Appearance Request for Non-DSPS Staff)*	9) Name of Case Advisor(s), if required:
☒ Open Session ☐ Closed Session	☐ Yes ☒ No	

10) Describe the issue and action that should be addressed:

1. WI ePDMP Operations
    a. Recent and Upcoming Releases
    b. EHR Integration Status
2. WI PDMP Outreach

11) Authorization

Marjorie Liu — 11/03/2025

Signature of person making this request — **Date**

Supervisor (if required) — **Date**

Executive Director signature (indicates approval to add post agenda deadline item to agenda) — **Date**

Directions for including supporting documents:
1. This form should be attached to any documents submitted to the agenda.
2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.
3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.

2023-2025 Development and Release Summary

Updated 11.03.2025

Release Date	Description
R33.24 **October 2025**	User Interface Updates: • Submitter: Remove Old Pharmacy Error Logs • Law Enforcement/Government Employee: Data Request Attestation Filename Criteria Language Update Website Management: • Delegate and Medical Coordinator Assistant Activation Email updates • User's First Name Updates to Reflect Name in LicensE
R33.23 **September 2025**	User Interface Updates: • Submitter: Update Manual Prescription Entry to ASAP4.2B • Submitter: Remove Old Pharmacy Error Logs • Dispensing Practitioner: account registration NPI field ready for entry Website Management: • Patient Matching Processing Job Enhancement • Patient's Gender on the Patient Report to pull in the Gender from the Most Recent Dispensing Admin Portal: Territories Added to inter-State Query Services Configuration Screen
R33.22 **August 2025**	**DEA -> NPI Systemic Changeover** • NPI information auto-populated on the Record Entry screen for Pharmacy and Dispensing Practitioner account types • Erroneously flagged errors of historical records removed from pharmacy error logs **Administration** Dispenser Report workflow fixes for Law Enforcement or Government user
R33.21 **July 2025**	**DEA -> NPI Systemic Changeover** • Dispenser Compliance Report reverted to using DEA first, switching to NPI on 12/1 • Pharmacy Zero Report auto populates NPI or leaves blank if account profile doesn't Include NPI • Data Submitter Guide updates **Administration** Fixes for Detailed Prescriber Monitoring Report **User Interface**

	• Dispenser Report download fixes for Law Enforcement or Government user • Submission data field PHA05 (Pharmacy Address 1) now accepts up to 55 characters
R33.20 **June 2025**	**Website changes adapting to NPI Requirements** Automated Notification Language Updates: • Submission compliance notification when NPI is missing • Gabapentin reporting guideline updates User Portal • Healthcare Professional Account – NPI requirement pop up updates • Law enforcement/investigative unit account: NPI added to prescriber and dispenser report request screen for Data Analytics • Metrics calculations revert to DEA-based
R33.19 **May 2025**	**Website changes adapting to NPI Requirements** Data Analytics • NPI Search Added to Detailed Prescriber Monitoring Report • NPI Added to Opioid Prescribing Practice Summary Report **Admin Portal Fixes and Updates**
R33.18 **April 2025**	Website Administration: • On-going Formatting and Calculation cleanups for automated Reports • NPI data field added to reports User Portal: NPI field added to search screen (for law enforcement, prosecutorial, and regulatory agencies)
R33.17 **March 2025**	User Portal: • Additional DEA fields in Prescribers account profile • NPI field added in Pharmacy account profile
R33.16 **February 2025**	Data Analytics Updates: • MME Conversion Factors updates • Buprenorphine exclusion rules applied to automated reporting of prescribing reports User Interface Updates • Healthcare Professionals - MME Calculator & Addiction Resource Updates • Investigators - Dispenser Report Request via User Accounts Administrative workflow updates - NPI added to Pending Account Registration Review Webpage Language Updates: Registration Page, Dashboard charts
R33.15.1 **February 2025**	Emergency Release to fix errors for out of state queries connecting via PMPi hub

R33.15 **January 2025**	Data Analytics Updates: • New admin tool of adding additional DEA numbers to automate Detailed Prescriber Monitoring Report • Formatting updates on Opioid Practice Summary Report User Interface Updates: • Pharmacy Account data revise/edit screen now with multiple DEAs dropdown selection
R33.14 **January 2025**	Updates to online form “Report Suspected Errors in WI ePDMP Date” PDF Pharmacy additional DEA display Increased License Number Character Limits from 7 to 8 File Processing Updates - Skipping Duplicate Files
R33.13 **December 2024**	User Interface: • Updated Text on the Delegate Management Screen • Updated Calculations for Daily Prescribing Volume Ranking for Opioids • License Number is no Longer a Required Field for a Medical Coordinator Account Admin Portal Updates: • Added Submission Date to Prescriber Alerts Table • NDC of Dispensed Medications displayed in the prescriber Report • Updated the Prescriber Query Compliance Report
R33.12 **November 2024**	ePDMP Webpage Updates: Contact Us info & user registration screen for Medical Coordinator and Researcher Analytics and Reports Updates- • Prescriber Monitoring Report Charts Readability • Prescriber Address populated on Dispensing History Details Administrative Workflow Enhancement: Alert reviewing screen updates
R33.11 **September 2024**	Non – HCP Alert Displays on Requested Reports Detailed Prescriber Monitoring Report Rework Updated Quarterly CSB Reports Prescriber Address Visible on Patient Report Table
R33.10 **August 2024**	Automation of Reports: • Opioid Prescribing Practice Summary Report Review • Quarterly Statistics for CSB Report Review • Detailed Prescriber Monitoring Report Review • Prescriber Address Populated on UI EHR Support Partial Refill Review
R33.9 **July 2024**	Opioid Prescribing Practice Summary Report Review Text Updates in UI Updates to notification emails Prescriber Query Compliance Report update
R33.8 **June 2024**	Opioid Prescribing Practice Summary Report Review Quarterly CSB Report Review Compound Drug UI

	Statistic utilization optimizations Addition of email address to non-HCP query requests
R33.7 **May 2024**	Dispenser Compliance Report Review Submitter/Dispenser Report Review
R33.6 **April 2024**	System Updates • Pending Account Changes UI language • UAT email notification links • Controlled Substance UI language Updated error messages for Submitters RXCheck 3.1 Update and Patch Statistics Dashboard populate counties' logic EHR Support
R33.5 **March 2024**	Statistics reporting updates EHR/Epic OAuth Support File Submission Queue processing
R33.4 **February 2024**	DEA File Updates LicenseE Update – State License Validation Training Materials Update File Processing support EHR support
R33.3 **January 2024**	LicenseE Update – New User Registration LicenseE Update – User Login Validation PDMP UI Page Text Updates • Home Page • Contact Us • Patient History Detail File Processing Support EHR Support
R33.2 **January 2024**	Pharmacy Users fixes • Zero reports • Revise/Correct/Void File Processing support EHR support
R33.1 **November 2023**	Utilization page updates PMPi States Admin Manage Alerts Timeout Patient Matching Updates

WI ePDMP Integration Services Summary

Updated 11.3.2025

Pending Health Systems and EHR Platforms	Status			Notes
Internal Medicine Associates	In discussion			
MECFS Clinic MN	In discussion			
Oak Leaf	In discussion			
CareATC	In discussion			
Connected Health Systems (61% of monthly patient queries)	**Free Pricing Model**	**Implementation Date**	**Est. Total # of Users**	**Notes**
Advent Health		03/05/2023	15	
Allina Health	Y	09/18/2023	100	
Ascension Wisconsin				
Aspirus Health Care				
Aurora Health Care	Y	05/08/2024	12,000	
Children's Hospital of Wisconsin	Y	09/01/2022	300	
Clark County	Y	11/01/2023		
Clean Slate	Y	09/01/2022	26	
CompuGroup Medical	Y	08/14/2024	50	
DrFirst	**Y**	05/01/2025		
Froedtert & the Medical College of Wisconsin			100	Pending signed Free agreement
GHC of South Central Wisconsin	Y	09/01/2024		
Gundersen Health System			800	Pending signed Free agreement
HealthPartners				
HSHS / Prevea Health	Y	01/01/2023	500	
M Health Fairview	Y	08/01/2022	30	
Marshfield Clinic	Y	09/01/2022	100	
Mayo Clinic				
Mercy Health	Y	08/01/2022	766	
Monroe Clinic				

NOVO Health Technology Group	Y	02/01/2023		
Ochin	Y	12/21/2022	100	
ProHealth Care	Y	1/17/2025		
QuadMed, LLC	Y	5/17/2023	40	
SSM Health				
Thedacare				Pending signed Free agreement
UnityPoint				
UW Health			4000	
Wisconsin Statewide Health Information Network	Y	09/01/2022	3500	

DrFirst Facilities	
Alay Health Team	National Medical Groups
Associated Mental Health Consultants	Nova Integrated Care LLC
Behavioral Health Svcs of Racine Co.	Oak Medical
Benjamin S. Gozon MDSC D/B/A Capitol Rehabilitation Clinic	Oral Surgery Associates of Milwaukee
Best Self Counseling Center	Orthopedic Hospital of Wisconsin
Christian Family Solutions	Pain Management and Treatment Center
Curana Health of Wisconsin	Pediatrics Associates
Door County Memorial Hospital	Reka Furedi MD
Dr. Colleen Worth, DNP, APNP	Red Oak Counseling
Empower Recovery	Regional Medical Center
Envision ADHD Clinic	Richland Hospital
FAMILY PSYCHIATRIC CARE, LLC	Rogers Memorial Hospital
Fort Healthcare	**RULA-WI**
GI Associates LLC	Sauk Prairie Memorial Hospital
Heartland Hospice	Shorewood Behavioral Health
Housing Initiatives	Third Eye Health
Jonathan Hoerl PMHNP	University of Wisconsin - Milwaukee
Kelly Pickens	Watertown Rainbow Hospice
Lake Superior Community Health Center	Wauwatosa Children's Clinic
Linc Health Clinic	Watertown Regional Medical Center

Lifestance Health WI	Yee Xiong MD
Madison Recovery Center	
Marshfield Clinic Health System	
Mental Health Specialty Group PA	
Mile Bluff Medical Center	
Milwaukee Medical Associate, SC	
Mindful Healing and Wellness LLC	

2025 WI PDMP Outreach Calendar

MONTH	EVENT	DESCRIPTION	DATES	NOTES
January	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	1/9/2025	Virtual; Quarterly Meeting
February				
March	Bi-Annual RxCheck Governance Board Meeting	Board Member-Participant; Interstate PDMP data exchange discussion	3/18-3/19/2025	San Diego, CA
April	Overdose Fatality Review (OFR) Local Community Meeting	PDMP Presentation; Portage County OFR Team Meeting	4/1/2025	Virtual
	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	4/10/2025	Virtual; Quarterly Meeting
May	Opioids, Stimulants, and Trauma Summit	Information Booth	5/6-5/8/2025	Wisconsin Dells
June	PMP InterConnect Steering Committee Meeting	Participant; Annual national meeting for PDMP administrators organized by National Association of Boards of Pharmacy (NABP)	6/23-6/24/2025	Mount Prospect, IL
July	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	7/10/2025	Virtual; Quarterly Meeting
August				
September	BadgerTraCS-PDMP Integration Outreach	Collaborative project across DOJ, DOT, & DSPS on promoting entry of law enforcement alerts	On-going	
October	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	10/9/2025	Virtual; Quarterly Meeting
	NASCSA Conference (National Association of State Controlled Substances Authorities)	Presenter; annual national meeting organized by NASCSA for government controlled substances authority, PDMP and healthcare professionals	10/20-10/23/2025	New Orleans, LA
November				
December	Bi-Annual RxCheck Governance Board Meeting	Board Member-Participant; Interstate PDMP data exchange discussion	TBD	TBD